Celldex Therapeutics CLDX EBITDA
EBITDA at other companies
Other financials
Where this comes from
Calculated from Celldex Therapeutics’s reported figures.
The official record: Celldex Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Celldex Therapeutics's ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Celldex Therapeutics's EBITDA?
- Celldex Therapeutics (CLDX) reported EBITDA of -$83.58M in Q1 2026.
- How has Celldex Therapeutics's EBITDA changed year-over-year?
- Celldex Therapeutics's EBITDA decreased by 35.1% year-over-year, from -$61.87M to -$83.58M.
- What is the long-term trend for Celldex Therapeutics's EBITDA?
- Over 4 years (2021 to 2025), Celldex Therapeutics's EBITDA has grown at a 42.9% compound annual growth rate (CAGR), from -$68.18M to -$283.99M.
- What does EBITDA mean?
- Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.